{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:43Z","timestamp":1792268623384,"version":"4.4.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejmech.2019.01.025","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T19:14:30Z","timestamp":1547493270000},"page":"225-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Hepatitis C \u2013 New drugs and treatment prospects"],"prefix":"10.1016","volume":"165","author":[{"given":"Marianna","family":"Zaj\u0105c","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-3671","authenticated-orcid":false,"given":"Izabela","family":"Muszalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Sobczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Dadej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jeli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.01.025_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNAS clone derived from a blood non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.01.025_bib2","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1093\/nar\/18.9.2685","article-title":"A\u00a0cDNA clone closely associated with non-A, non-B hepatitis","volume":"18","author":"Maeno","year":"1990","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2019.01.025_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib4","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib5","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/j.gastro.2012.01.045","article-title":"Is hepatitis C virus carcinogenic?","volume":"142","author":"Lemon","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1099\/0022-1317-78-2-321","article-title":"The origin of hepatitis C virus genotypes","volume":"78","author":"Smith","year":"1997","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1099\/0022-1317-82-4-693","article-title":"The origin and evolution of hepatitis viruses in humans","volume":"82","author":"Simmonds","year":"2001","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib10","first-page":"121","article-title":"Advanced liver disease: what every hepatitis C virus treater should know","volume":"19","author":"Sherman","year":"2011","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Clinical Practice Guidelines","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib13","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cid\/cis227","article-title":"Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV\/AIDS","volume":"54","author":"Ford","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.01.025_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.01.025_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","article-title":"The hepatitis C virus epidemic among injecting drug users","volume":"5","author":"Pybus","year":"2005","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/2231-0738.147455","article-title":"A\u00a0review of the current anti-HCV therapy: are we finally ready for interferon-free regimens","volume":"4","author":"Anantharamu","year":"2014","journal-title":"Inter. J. Nutr. Pharmacol. Neurol. Dis."},{"key":"10.1016\/j.ejmech.2019.01.025_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/omi.1.2000.5.129","article-title":"Genome of human hepatitis C virus (HCV). Gene organization, sequence diverity, and variation","volume":"5","author":"Kato","year":"2000","journal-title":"Microb. Comp. Genom."},{"key":"10.1016\/j.ejmech.2019.01.025_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0168-1702(95)00034-N","article-title":"Transciptional regulation of cellular and viral promoters by the hepatitis C virus core protein","volume":"37","author":"Ray","year":"1995","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2019.01.025_bib20","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1128\/jvi.67.10.5823-5832.1993","article-title":"Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells","volume":"67","author":"Shih","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1 \u2013 E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1099\/vir.0.79967-0","article-title":"Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver","volume":"85","author":"Nielsen","year":"2004","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib23","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/0168-8278(91)90015-4","article-title":"Sequence variation in hepatitis C viral isolates","volume":"13","author":"Weiner","year":"1991","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib24","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/JVI.76.8.3720-3730.2002","article-title":"Subcellular localization and topology of the p7 polypeptide of hepatitis C virus","volume":"76","author":"Carrere-Kremer","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature12283","article-title":"Unusual architecture of the p7channel from hepatitis C virus","volume":"498","author":"QuYang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.01.025_bib26","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1128\/jvi.69.12.7461-7471.1995","article-title":"The NS2 protein of hepatitis C virus is a transmembrane polypeptide","volume":"69","author":"Santolini","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib27","doi-asserted-by":"crossref","first-page":"33228","DOI":"10.1074\/jbc.M202304200","article-title":"Membrane topology of the hepatitis C virus NS2 protein","volume":"277","author":"Yamaga","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib28","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1073\/pnas.90.22.10583","article-title":"Rice, A second hepatitis C virus-encoded protease","volume":"90","author":"A.Grakoui","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2019.01.025_bib29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/jvi.67.3.1385-1395.1993","article-title":"Expression and identification of hepatitis C virus polyprotein cleavage products","volume":"67","author":"Grakoui","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib30","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1128\/JVI.79.5.2700-2708.2005","article-title":"Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasom","volume":"79","author":"Franck","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib31","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/jvi.67.7.3835-3844.1993","article-title":"Nonstructural protein 3 of the hepatitis C virus encodes a serine-type protease required for cleavage at the NS3\/4 and NS4\/5 junction","volume":"67","author":"Bartenschlager","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib32","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/jvi.67.5.2832-2843.1993","article-title":"Characterization of the hepatitis C virus-encoded serine protease: determination of protease-dependent polyprotein cleavage sites","volume":"67","author":"Grakoui","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib33","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/jvi.67.7.4017-4026.1993","article-title":"NS3 is a serine protease required for processing of hepatitis C virus polyprotein","volume":"67","author":"Tomei","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib34","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1128\/jvi.69.12.7519-7528.1995","article-title":"Complex formation between the NS3 serine-type protease of the hepatitis C virus and NS4A and its importance for polyprotein maturation","volume":"69","author":"Bartenschlager","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib35","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1128\/jvi.69.7.4373-4380.1995","article-title":"A\u00a0central region in the hepatitis C virus NS4A protein allows formation of the active NS3-NS4A serine protease complex in\u00a0vivo and in\u00a0vitro","volume":"69","author":"Lin","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib36","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/jvi.69.3.1575-1581.1995","article-title":"Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing","volume":"69","author":"Tanji","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"Foy","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.01.025_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1432-1033.1997.00047.x","article-title":"DNA helicase activity of the hepatitis C virus nonstructural protein 3","volume":"250","author":"Gwack","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib39","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1128\/jvi.70.12.8477-8484.1996","article-title":"The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3)","volume":"70","author":"Tai","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib40","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib41","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1128\/JVI.77.9.5487-5492.2003","article-title":"Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons","volume":"77","author":"Gosert","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.01.025_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4254\/wjh.v8.i2.92","article-title":"Chronic hepatitis C: this and the new era of treatment","volume":"18","author":"Bertino","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2011.12.007","article-title":"Hepatitis C virus host cell entry","volume":"2","author":"Ploss","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chom.2010.12.002","article-title":"Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment","volume":"9","author":"Reiss","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2019.01.025_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molmed.2014.02.002","article-title":"Hepatitis C treatment: an incipient therapeutic revolution","volume":"20","author":"deLemos","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib51","first-page":"569","article-title":"Hepatitis C virus RNA replication and assembly. Living on the fat of the land, cell host","volume":"16","author":"Paul","year":"2014","journal-title":"Microbe"},{"key":"10.1016\/j.ejmech.2019.01.025_bib52","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5114\/ceh.2017.67782","article-title":"Recommendations for the treatment of hepatitis C in 2017","volume":"3","author":"Halota","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct acting agents (DAAs) \u2013 a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.01.025_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a significant paradigm change in HCV treatment","volume":"3","author":"McQuaid","year":"2015","journal-title":"J.\u00a0Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","article-title":"Hepatitis C virus NS3\/4A protease inhibitors","volume":"30","author":"McCauley","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib57","first-page":"241","article-title":"Simeprevir on the treatment of hepatitis C virus infection","volume":"7","author":"Izquierdo","year":"2014","journal-title":"Pharmacogenomics Personalized Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib58","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3\/4A protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbagen.2004.02.008","volume":"1672","author":"Poliajkow","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2019.01.025_bib60","series-title":"Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitor. Targeting Different Genotypes and Drug-Resistant Variants","author":"Belfrage","year":"2015"},{"key":"10.1016\/j.ejmech.2019.01.025_bib61","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","volume":"142","author":"Schaefer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib64","unstructured":"Vosevi (sofosbuvir, welpatasvir, voxilaprevir). FDA Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209195s002lbl.pdf (accessed 17 July 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib65","unstructured":"Mavyret tablets (glecaprevir\/pibrentasvir) tablets: FDA Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s000lbl.pdf (accessed 17 July 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib66","unstructured":"Olysio (Simeprevir) capsules: FDA Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205123s012lbl.pdf (accessed 02 July 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib67","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1016\/j.bmcl.2016.07.057","article-title":"Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors","volume":"26","author":"Tong","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.01.025_bib68","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.00146-11","article-title":"Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures","volume":"55","author":"Lemm","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.01.025_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/ml4003293","article-title":"Potent hepatitis C virus NS5A inhibitors containing a benzidine core","volume":"5","author":"Bae","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.01.025_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/HMER.S72429","article-title":"Paritaprevir\/ritonavir \u2013 ombitasvir and dasabuvir the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review","volume":"8","author":"Hussaini","year":"2016","journal-title":"Hepat. Med."},{"key":"10.1016\/j.ejmech.2019.01.025_bib71","unstructured":"DAKLINZA (daclatasvir) tablets: FDA Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/206843s006lbl.pdf (accessed 06 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib72","unstructured":"SOVALDI (sofosbuvir) tablets: FDA Highlights of Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204671s002lbl.pdf (accessed 06 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib73","unstructured":"HARVONI (ledipasvir and sofosbuvir) tablets: FDA Highlights of Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205834s001lbl.pdf (accessed 06 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib74","unstructured":"TECHNIVIE ((ombitasvir, paritaprevir and ritonavir) tablets: FDA Highlights of Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207931s007s009lbl.pdf (accessed 10 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib75","unstructured":"VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets): FDA Highlights of Prescibing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf (accessed 10 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib76","unstructured":"Epclusa (sofosbuvir and welpatasvir) Tablets: FDA Highlights of Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208341s000lbl.pdf (accessed 10 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.12068","article-title":"New therapeutic strategies in HCV: polymerase inhibitors","volume":"33","author":"Gerber","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2019.01.025_bib78","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/j.gastro.2016.11.047","article-title":"Daclatasvir prevents Hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites","volume":"7","author":"Boson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib79","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1021\/jm501291c","article-title":"Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition","volume":"57","author":"Nettles","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib80","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib81","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/DDDT.S40310","article-title":"Daclatasvir: potential role in hepatitis C","volume":"7","author":"Lee","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejmech.2019.01.025_bib82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1021\/jm5000936","article-title":"Introduction to hepatitis C virus (HCV) therapies special thematic issue","volume":"57","author":"Meanwell","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1756283X13515825","article-title":"Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential","volume":"7","author":"Stedman","year":"2014","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib84","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib85","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2174\/156802607781212211","article-title":"Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase","volume":"7","author":"U.Koch","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"G\u00f6tte","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib87","first-page":"92","article-title":"Chronic hepatitis C: this and the new era of treatment, World","volume":"8","author":"Bertino","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib88","doi-asserted-by":"crossref","first-page":"11462","DOI":"10.2174\/092986708784638906","article-title":"Non-nucleoside inhibitory of NS5B polymerase binding to allosteric sites: 3D \u2013 QSAR and molecular docking studies","volume":"15","author":"Cao","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib89","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/med.21271","article-title":"Structure-activity relationship in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research","volume":"5","author":"Haudecoeur","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.01.025_bib90","unstructured":"Glecaprevir\/Pirbentasvir (MAVIRET): Non-clinical Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209394Orig1s000PharmR.pdf (accessed 23 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib91","unstructured":"Zepatier (grazoprevir\/elbasvir). Clinical Pharmacology Review(s). http:\/\/www.accessdata.fda.gov.\/drugsatfda_docs\/nda\/2016\/208261Orig1s000ClinPharmR.pdf (accessed 23 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib92","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/dmd.115.067496","article-title":"Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans","volume":"44","author":"Shen","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.01.025_bib93","unstructured":"Simeprevir Clinical Pharmacology Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205123Orig1s000ClinPharmR.pdf (accessed 23 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib94","unstructured":"Vosevi (Sofosbuvir, velpatasvir, voxilaprevir). Clinical Pharmacology and Biopharmaceutics Review(s). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209195Orig1s000ClinPharmR.pdf (accessed 23 August 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib95","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/dmd.115.068866","article-title":"Biotransformation of daclatasvir in\u00a0vitro and in nonclinical species: formation of the main metabolite by pyrrolidine \u03b4-oxidation and rearrangement","volume":"44","author":"Li","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.01.025_bib96","unstructured":"Zepatier (grazoprevir\/elbasvir). Clinical Pharmacology Review(s). https:\/\/www.accessdata.fda.gov.\/drugsatfda_docs\/nda\/2016\/208261Orig1s000ClinPharmR.pdf (accessed 05 September 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib97","unstructured":"Harvoni (ledipasvir and sofosbuvir): Pharmacology Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205834Orig1s000PharmR.pdf (accessed 05 September 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib98","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.115.067488","article-title":"Metabolism and disposition of hepatitis C protease inhibitor paritaprevir in humans","volume":"44","author":"Shen","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.01.025_bib99","unstructured":"Glecaprevir\/Pibrentasvir (MAVIRET): Non-clinical Review(s). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209394Orig1s000PharmR.pdf (accessed 12 September 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib100","unstructured":"Australian Public Assessment Report for: Sofosbuvir\/Velpatasvir https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-sofosbuvir-velpatasvir-171108.pdf (accessed 12 September 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib101","unstructured":"Epclusa (Sofosbuvir, Velpatasvir): Pharmacology Review(s).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208341Orig1s000PharmR.pdf (accessed 12 September 2018)."},{"key":"10.1016\/j.ejmech.2019.01.025_bib102","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.2174\/09298673113209990178","article-title":"A\u00a0novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir","volume":"20","author":"Gentile","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.01.025_bib103","first-page":"746A","article-title":"Population Pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV infected adult subjects","volume":"58","author":"Kirby","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib104","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1124\/dmd.115.067512","article-title":"Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans","volume":"44","author":"Shen","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.01.025_bib105","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3390\/v7122968","article-title":"Mechanisms of hepatitis C viral resistance to direct acting antivirals","volume":"7","author":"Ahmed","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2019.01.025_bib106","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.01.025_bib107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis V virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2019.01.025_bib108","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.01.025_bib109","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib111","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02264-15","article-title":"Potent antiviral activities of the direct-actinh antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.01.025_bib112","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/v7112898","article-title":"Hagents to prevent and cure hepatitis C virus infection","volume":"7","author":"Zeisel","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2019.01.025_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01707","article-title":"Interferon lambda genetics and biology in regulation of viral control","volume":"8","author":"Hemann","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib114","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3748\/wjg.v22.i2.862","article-title":"Status of hepatitis C virus vaccination: recent update","volume":"22","author":"Abdelwahab","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2019.01.025_bib115","doi-asserted-by":"crossref","first-page":"11984","DOI":"10.3748\/wjg.v21.i42.11984","article-title":"Progress in the development of vaccines for hepatitis C virus infection","volume":"21","author":"Ghasemi","year":"2015","journal-title":"World J. Gastroenterol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419300352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:48:02Z","timestamp":1759326482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419300352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":114,"alternative-id":["S0223523419300352"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.025","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C \u2013 New drugs and treatment prospects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}